These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. Gingival fibroblasts are better at inhibiting osteoclast formation than periodontal ligament fibroblasts. de Vries TJ; Schoenmaker T; Wattanaroonwong N; van den Hoonaard M; Nieuwenhuijse A; Beertsen W; Everts V J Cell Biochem; 2006 May; 98(2):370-82. PubMed ID: 16440316 [TBL] [Abstract][Full Text] [Related]
66. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014 [TBL] [Abstract][Full Text] [Related]
67. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. Hofbauer LC; Khosla S; Dunstan CR; Lacey DL; Boyle WJ; Riggs BL J Bone Miner Res; 2000 Jan; 15(1):2-12. PubMed ID: 10646108 [TBL] [Abstract][Full Text] [Related]
68. CSF-1, RANKL and OPG regulate osteoclastogenesis during murine tooth eruption. Heinrich J; Bsoul S; Barnes J; Woodruff K; Abboud S Arch Oral Biol; 2005 Oct; 50(10):897-908. PubMed ID: 16137499 [TBL] [Abstract][Full Text] [Related]
69. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. Liu XH; Kirschenbaum A; Yao S; Levine AC Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359 [TBL] [Abstract][Full Text] [Related]
70. [The effects of 17 beta-estradiol on the expression of osteoprotegerin, the ligand of osteoprotegerin and related cytokines in osteosarcoma MG63 cells]. Su X; Liao EY; Peng J; Wu XP Zhonghua Nei Ke Za Zhi; 2003 Nov; 42(11):800-3. PubMed ID: 14636471 [TBL] [Abstract][Full Text] [Related]
71. Nicotine and lipopolysaccharide stimulate the formation of osteoclast-like cells by increasing macrophage colony-stimulating factor and prostaglandin E2 production by osteoblasts. Tanaka H; Tanabe N; Shoji M; Suzuki N; Katono T; Sato S; Motohashi M; Maeno M Life Sci; 2006 Mar; 78(15):1733-40. PubMed ID: 16266722 [TBL] [Abstract][Full Text] [Related]
72. High extracellular calcium affects osteoclastogenesis in mouse bone marrow cell culture. Takahashi E; Mukohyama H; Aoki K; Duarte WR; Lerner UH; Ohya K; Omura K; Kasugai S J Med Dent Sci; 2002 Dec; 49(4):109-20. PubMed ID: 12641381 [TBL] [Abstract][Full Text] [Related]
73. Nitric oxide donor increases osteoprotegerin production and osteoclastogenesis inhibitory activity in bone marrow stromal cells from ovariectomized rats. Wang FS; Wang CJ; Chen YJ; Huang YT; Huang HC; Chang PR; Sun YC; Yang KD Endocrinology; 2004 May; 145(5):2148-56. PubMed ID: 14962990 [TBL] [Abstract][Full Text] [Related]
74. Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. Itonaga I; Sabokbar A; Sun SG; Kudo O; Danks L; Ferguson D; Fujikawa Y; Athanasou NA Bone; 2004 Jan; 34(1):57-64. PubMed ID: 14751563 [TBL] [Abstract][Full Text] [Related]
75. Nitric oxide regulates receptor activator of nuclear factor-kappaB ligand and osteoprotegerin expression in bone marrow stromal cells. Fan X; Roy E; Zhu L; Murphy TC; Ackert-Bicknell C; Hart CM; Rosen C; Nanes MS; Rubin J Endocrinology; 2004 Feb; 145(2):751-9. PubMed ID: 14563699 [TBL] [Abstract][Full Text] [Related]
76. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Lacey DL; Tan HL; Lu J; Kaufman S; Van G; Qiu W; Rattan A; Scully S; Fletcher F; Juan T; Kelley M; Burgess TL; Boyle WJ; Polverino AJ Am J Pathol; 2000 Aug; 157(2):435-48. PubMed ID: 10934148 [TBL] [Abstract][Full Text] [Related]
77. Bumetanide, the specific inhibitor of Na+-K+-2Cl- cotransport, inhibits 1alpha,25-dihydroxyvitamin D3-induced osteoclastogenesis in a mouse co-culture system. Lee HA; Jeong H; Kim EY; Nam MY; Yoo YJ; Seo JT; Shin DM; Ohk SH; Lee SI Exp Physiol; 2003 Sep; 88(5):569-74. PubMed ID: 12955156 [TBL] [Abstract][Full Text] [Related]
79. The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. Mukohyama H; Ransjö M; Taniguchi H; Ohyama T; Lerner UH Biochem Biophys Res Commun; 2000 Apr; 271(1):158-63. PubMed ID: 10777696 [TBL] [Abstract][Full Text] [Related]
80. Primary human bone marrow adipocytes support TNF-α-induced osteoclast differentiation and function through RANKL expression. Goto H; Hozumi A; Osaki M; Fukushima T; Sakamoto K; Yonekura A; Tomita M; Furukawa K; Shindo H; Baba H Cytokine; 2011 Dec; 56(3):662-8. PubMed ID: 21963155 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]